Skip to content
DataLookout
Menu

NCT07921966

Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pharmacokinetic parameters of olanzapine in plasma
Timeframe: Time zero to 14 days postdose

Arms and interventions

NRL 1004 25 mg/mL solutionExperimental

NRL-1004 (olanzapine nasal spray), 25 mg/mL solution

NRL-1004 50 mg/mL solutionExperimental

NRL-1004 (olanzapine nasal spray), 50 mg/mL solution

NRL-1004 75 mg/mL solutionExperimental

NRL-1004 (olanzapine nasal spray), 75 mg/mL solution

NRL-1004 100 mg/mL solutionExperimental

NRL-1004 (olanzapine nasal spray), 100 mg/mL solution

ZYPREXA IM 10mg/vialActive comparator

ZYPREXA IntraMuscular (olanzapine) Injection, Powder, for Solution for Intramuscular use, 10 mg/vial

Drugs: NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg, NRL-1004 7.5 mg, NRL-1004 10.0 mg